These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29436642)

  • 1. Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells.
    Lim ST; Jeon YW; Gwak H; Kim SY; Suh YJ
    Mol Med Rep; 2018 Apr; 17(4):5581-5588. PubMed ID: 29436642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
    Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R
    J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Ruxolitinib and Calcitriol Combination Treatment on Various Molecular Subtypes of Breast Cancer.
    Schneider J; Jeon YW; Suh YJ; Lim ST
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of mild hyperthermia plus docetaxel therapy on ER(+/-) breast cancer cells and action mechanisms.
    Lv F; Yu Y; Zhang B; Liang D; Li ZM; You W
    J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):870-876. PubMed ID: 24337851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line.
    Guvenir Celik E; Eroglu O
    Mol Biol Rep; 2023 Jan; 50(1):319-329. PubMed ID: 36331743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers.
    Regua AT; Bindal S; Najjar MK; Zhuang C; Khan M; Arrigo ABJ; Gonzalez AO; Zhang XR; Zhu JJ; Watabe K; Lo HW
    Cancer Lett; 2024 Aug; 597():217023. PubMed ID: 38852701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1.
    Celik EG; Eroglu O
    Mol Biol Rep; 2024 Jul; 51(1):832. PubMed ID: 39037638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy.
    García-Quiroz J; García-Becerra R; Barrera D; Santos N; Avila E; Ordaz-Rosado D; Rivas-Suárez M; Halhali A; Rodríguez P; Gamboa-Domínguez A; Medina-Franco H; Camacho J; Larrea F; Díaz L
    PLoS One; 2012; 7(9):e45063. PubMed ID: 22984610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.
    Doheny D; Sirkisoon S; Carpenter RL; Aguayo NR; Regua AT; Anguelov M; Manore SG; Arrigo A; Jalboush SA; Wong GL; Yu Y; Wagner CJ; Chan M; Ruiz J; Thomas A; Strowd R; Lin J; Lo HW
    Oncogene; 2020 Oct; 39(42):6589-6605. PubMed ID: 32929154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
    Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
    Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcitriol and 20(S)-protopanaxadiol synergistically inhibit growth and induce apoptosis in human prostate cancer cells.
    Ben-Eltriki M; Deb S; Adomat H; Tomlinson Guns ES
    J Steroid Biochem Mol Biol; 2016 Apr; 158():207-219. PubMed ID: 26709138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR‑135b‑5p enhances the sensitivity of HER‑2 positive breast cancer to trastuzumab via binding to cyclin D2.
    Li Z; Qin Y; Chen P; Luo Q; Shi H; Jiang X
    Int J Mol Med; 2020 Oct; 46(4):1514-1524. PubMed ID: 32700749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
    Hao X; Xing W; Yuan J; Wang Y; Bai J; Bai J; Zhou Y
    Invest New Drugs; 2020 Jun; 38(3):610-620. PubMed ID: 31227936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.
    Wang YX; Gao JX; Wang XY; Zhang L; Liu CM
    Tumour Biol; 2012 Aug; 33(4):957-66. PubMed ID: 22252523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
    Corkery B; Crown J; Clynes M; O'Donovan N
    Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 tyrosine kinase inhibitor AG490 suppresses cell growth and invasion of gallbladder cancer cells via inhibition of JAK2/STAT3 signaling.
    Fu LX; Lian QW; Pan JD; Xu ZL; Zhou TM; Ye B
    J Biol Regul Homeost Agents; 2017; 31(1):51-58. PubMed ID: 28337870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC.
    Hu Y; Hong Y; Xu Y; Liu P; Guo DH; Chen Y
    Apoptosis; 2014 Nov; 19(11):1627-36. PubMed ID: 25213670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.
    Premkumar DR; Jane EP; Pollack IF
    Cancer Biol Ther; 2015; 16(2):233-43. PubMed ID: 25482928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
    Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
    Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.